A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation. We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, “Plasma” includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.4B | 1.3B | 1.2B | 993M | 870M |
| Net Income | 175M | 168M | 118M | 115M | 43M | 79M |
| EPS | $3.69 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 |
| Free Cash Flow | 308M | 142M | 144M | 82M | 76M | 72M |
| ROIC | 10.9% | 10.6% | 8.9% | 10.8% | 4.4% | 8.4% |
| Gross Margin | 59.4% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% |
| Debt/Equity | 1.34 | 1.49 | 0.84 | 0.94 | 1.03 | 0.99 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 251M | 222M | 165M | 156M | 81M | 90M |
| Operating Margin | 19.0% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% |
| ROE | 19.2% | 18.8% | 13.2% | 14.7% | 5.9% | 10.9% |
| Shares Outstanding | 47M | 51M | 51M | 52M | 52M | 51M |
HAEMONETICS CORP passes 7 of 9 quality checks, indicating strong fundamentals.
HAEMONETICS CORP trades at 16.7x trailing earnings, compared to its 15-year median P/E of 69.8x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 9.1x vs a median of 40.9x. The company's 5-year average ROIC is 8.6% with a gross margin of 51.4%. Total shareholder yield (buybacks) is 7.9%. At current prices, the estimated annualized return to fair value is +10.0%.
HAEMONETICS CORP (HAE) has a current P/E ratio of 16.7, compared to its historical median P/E of 69.8. The stock is currently considered Cheap based on its historical valuation range.
HAEMONETICS CORP (HAE) has a 5-year average return on invested capital (ROIC) of 8.6%. This is below average and may indicate limited pricing power.
HAEMONETICS CORP (HAE) has a market capitalization of $2.8B. It is classified as a mid-cap stock.
HAEMONETICS CORP (HAE) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 7.94%.
Based on historical P/E analysis, HAEMONETICS CORP (HAE) appears cheap. The current P/E of 16.7 is 76% below its historical median of 69.8. The estimated fair value CAGR (P/E method) is 14.4%.
HAEMONETICS CORP (HAE) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
HAEMONETICS CORP (HAE) reported annual revenue of $1.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
HAEMONETICS CORP (HAE) has a net profit margin of 12.3%. This is a healthy margin.
HAEMONETICS CORP (HAE) generated $142 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
HAEMONETICS CORP (HAE) has a debt-to-equity ratio of 1.49. This indicates moderate leverage.
HAEMONETICS CORP (HAE) reported earnings per share (EPS) of $3.31 in its most recent fiscal year.
HAEMONETICS CORP (HAE) has a return on equity (ROE) of 18.8%. This indicates the company generates strong returns for shareholders.
HAEMONETICS CORP (HAE) has a 5-year average gross margin of 51.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for HAEMONETICS CORP (HAE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
HAEMONETICS CORP (HAE) has a book value per share of $16.20, based on its most recent annual SEC filing.
No recent press releases.